US 12,227,572 B2
Monoclonal antibodies against the beta chain region of human TRBV9
Olga Vladimirovna Britanova, Moscow (RU); Dmitry Borisovich Staroverov, Moscow (RU); Anna Valentinovna Evstrateva, G. Pitkyaranta (RU); Alexey Konstantinovich Misorin, Saint Petersburg (RU); Timofey Aleksandrovich Nemankin, Saint Petersburg (RU); Mariia Aleksandrovna Shchemeleva, Saint-Petersburg (RU); Anna Konstantinovna Vladimirova, Saint Petersburg (RU); Arina Vitalevna Anikina, Moscow (RU); Roman Alekseevich Ivanov, Moscow (RU); Dmitry Valentinovich Morozov, Saint Petersburg (RU); Pavel Andreevich Iakovlev, Saint Petersburg (RU); and Sergey Anatolievich Lukyanov, Moscow (RU)
Appl. No. 17/417,686
Filed by JOINT STOCK COMPANY “BIOCAD”, Saint Petersburg (RU)
PCT Filed Feb. 20, 2020, PCT No. PCT/RU2020/050024
§ 371(c)(1), (2) Date Jun. 23, 2021,
PCT Pub. No. WO2020/139175, PCT Pub. Date Jul. 2, 2020.
Claims priority of application No. 2018146031 (RU), filed on Dec. 25, 2018.
Prior Publication US 2022/0112286 A1, Apr. 14, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2809 (2013.01) [A61K 39/00 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/92 (2013.01)] 16 Claims
 
1. A monoclonal antibody or antigen-binding fragment thereof that specifically binds to the beta chain region of the human TCR TRBV9, comprising a heavy chain variable domain comprising the amino acid sequence of SEQ ID No: 16 and a light chain variable domain comprising the amino acid sequence of SEQ ID No: 18.